Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Theralase Technologies
1 program
1
TLD1433 infusion and photodynamic therapyPhase 11 trial
Active Trials
NCT03053635CompletedEst. Aug 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Theralase TechnologiesTLD1433 infusion and photodynamic therapy

Clinical Trials (1)

NCT03053635Theralase TechnologiesTLD1433 infusion and photodynamic therapy

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Start: Dec 2016Est. completion: Aug 2018
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)